FRONTIER BIOTECHNOLOGIES Inc.

News

   
Home>Media

Frontier Biotechnologies announced phase I clinical result of COVID-19 treatment FB2001 at the International Conference on Emerging Infectious Diseases (ICEID)

On August 8, local time in the United States, Frontier Biotechnologies (Nanjing) Co., Ltd. (hereinafter referred to as the "Company", stock code: 688221. SH) announced the results of the Phase I clinical research of the small molecule drug FB2001 (common name: Bofutrelvir) at the 11th Inte...
  • 2022-08-09  13:37:44
details>

Frontier Biotechnologies signed a strategic cooperation agreement with Kangsheng Global to jointly develop the infectious disease diagnosis and treatment market

Frontier Biotech and Kangsheng Global have reached a number of cooperation Consensus on the promotion of anti-infection diagnostic testing, and are committed to jointly promoting the improvement of the diagnosis and treatment level of infectious diseases in China. This partnership ensures both compa...
  • 2022-08-08  13:35:02
details>

Frontier Biotechnologies was awarded the "2022 China Biopharmaceutical Industry Value List - Top 10 Most Growing Small Molecule Innovative Pharmaceutical Enterprises"

On August 4, 2022, the 2022 China Biopharmaceutical Industry Value List Awards Ceremony was held in Suzhou, and Frontier Biotechnologies Inc. (stock code "688221.SH") was awarded the "2022 China Biopharmaceutical Industry Value List - Top 10 Most Growing Small Molecule Innovative Phar...
  • 2022-08-05  13:33:51
details>

First Scientific Education Collaboration with Ministry of Commerce of the People’s Republic of China and Beijing Holley-Cotec Pharamceuticals for Officials of Developing Countries

Frontier Biotechnologies was invited by the Ministry of Commerce of the People’s Republic of China and Beijing Holley-Cotec Pharamceuticals Co. Ltd to deliver a training lecture titled “HIV Treatment Trends and Introduction of Albuvirtide” at the “Seminar for Officials of Developing Countries”, incl...
  • 2022-07-25  15:46:58
details>

Frontier Enters Into A New Partnership With Avacare Health To Continue Its Global Expansion Into East And West Africa

Frontier Biotechnologies Inc. (Frontier) is pleased to announce our partnership with Avacare Health Group (Avacare Health) to expand access for Albuvirtide to people living with HIV (PLHIV) in Kenya, Nigeria, Tanzania and Malawi, thus reaching the key countries in eastern and western Africa.There ar...
  • 2022-07-25  15:45:07
details>

Aikening®(Albuvirtide) is a Recommended Regimen for Post-Exposure AIDS Patients in the Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS (2021 Edition)

In October 2021, in the “13th National AIDS and Hepatitis C Conference of the Chinese Medical Association”, organized by the AIDS Group of the Chinese Society of Infectious Diseases, Chinese Medical Association, the Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS (2021 Edition) (hereinaft...
  • 2022-07-05  15:42:55
details>

Aikening® Brings about A New Anti-HIV Combination Therapy! Results of Phase III Clinical Study TALENT Launched in IAS

On July 18, 2021 local time, the 11th International AIDS Society (IAS) Conference on HIV Science was held in Berlin, Germany. At this conference, Frontier Biotech (stock code: 688221.SH) released the key research results of its Phase III clinical study (TALENT study) on the long-acting anti-HIV-1 fu...
  • 2022-07-05  15:39:10
details>

Results of Phase III TALENT Study on Frontier Biotech’s Long-acting Anti-HIV Fusion Inhibitor Albuvirtide Were Published in An Authoritative International Medical Journal

On June 10, 2022, the Journal Of Infection (ISSN: 0163-4453, eISSN: 1532-2742), an authoritative international medical journal, published online the 48-week final results of Phase III clinical TALENT study on Frontier Biotech’s long-acting anti-HIV fusion inhibitor Albuvirtide (ABT). In 2018, based ...
  • 2022-06-22  15:36:07
details>

Aikening® Launch in Azerbaijan

Frontier Biotechnologies announced that the Azerbaijan Republic Ministry of Health approved Aikening® (Albuvirtide), the first long-acting intravenous infusion for the treatment of HIV-1 infection in adults. Aikening® is a new fusion inhibitor given once weekly, used in combination dual th...
  • 2022-06-22  10:08:57
details>

An Investigator Initiated Clinical Trial of Inhaled Bofutrelvir for Post-Exposure Prophylaxis in Close Contacts of COVID-19 Patients

Shanghai Ruijin Hospital recently announced that it has initiated an investigator-initiated clinical trial (IIT) to evaluate the safety and efficacy of Bofutrelvir administered by inhalation for post-exposure prophylaxis in close contacts of COVID-19 (NCT05415241). It is a single-arm, open-label, m...
  • 2022-06-15  10:08:28
details>

FB2001 (Bofutrelvir) Phase II/III Clinical Trial Protocol Approved by NMPA

Frontier Biotech (stock code: 688221.SH) announced that the Phase II/III clinical study protocol of FB2001 (generic name: Bofutrelvir) is approved by the Center for Drug Evaluation, NMPA. The study is a worldwide multi-center, randomized, double-blind and placebo-controlled Phase II/III trial to ev...
  • 2022-04-27  10:07:38
details>

Frontier Biotech opens a new manufacture facility in Chengdu ——Aikening ®, a novel long-acting HIV medicine, receives a production capability boost

On July 15, 2021, The openning ceremony of a new state of the art peptide manufacture facility was held in Jintang, Chengdu. The successful completion of the facility marks the successful industrialization of Aikening® in Jintang.Aiming at intelligent manufacturing, high efficiency and eco syst...
  • 2021-08-31  16:54:43
details>

Develop Innovative Therapies to Better Human Lives

Frontier Biotechnologies Inc.（Nanjing）
Medicalinfo@frontierbiotech.com
jubao@frontierbiotech.com
Adverse events report mailbox：pv@frontierbiotech.com
Copyright © 2016 Corporation All Rights ReservedFrontier Biotechnologies Inc.
Full Prescribing Information | Introduction for Use | About Frontier

This site is for informational purposes only
and is intended for Healthcare Professionals.

Are you a Healthcare Professional?

I am a licensed Healthcare Professional I am a Patient or Caregiver